Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of escalating doses of ARN-509 (apalutamide) in combinatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ARN-509 (apalutamide) (apalutamide)
• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED